CompletedNot Applicable

Glucocorticoids and Bone in Graves' Ophthalmopathy

Denmark39 participantsStarted 2017-06-07

Plain-language summary

Continuous use of systemic glucocorticoids decreases bone mineral density and increases fracture risk. Graves' orbitopathy is treated with weekly infusion of high-dose intravenous glucocorticoid. The investigators aim at investigating whether this treatment regimen also affects bone metabolism.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Graves Ophthalmopathy that requires treatment with intra-venous methylprednisolone Exclusion Criteria: * Treatment with osteoporosis medication * Primary hyperparathyroidism * Hypoparathyroidism * Vitamin D \< 20mmol/L * Estimated glomerular filtration rate \< 30 mL/min * Liver disease * Peroral treatment with glucocorticoids within last three months prior to inclusion

What they're measuring

Percent Change Lumbar Spine Bone Mineral Density

Timeframe: 12 weeks

Trial details

NCT IDNCT03122847

SponsorTorben Harsløf

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-07-14

Results submitted2023-06-14

View on ClinicalTrials.gov More Graves Ophthalmopathy trials